Department of Ophthalmology, Assaf Harofeh Medical Center, Tel Aviv University, Zrifin, Israel.
Curr Opin Ophthalmol. 2011 Sep;22(5):407-12. doi: 10.1097/ICU.0b013e328349b0b6.
Since the advent of botulinum neurotoxin (BoNT) in the facial cosmetic field, it has become the leading nonsurgical cosmetic procedure in the USA, and several different formulations are currently in use. The aim of this study is to review the major 'players' in order to help the physician understand the clinically relevant dissimilarities between the products and by that promote treatment efficacy and patient satisfaction.
The different available formulations can be classified into two groups by the existence of absence of complexing proteins. Most of the influence that was previously attributed to these proteins has been found to be less relevant clinically, the immune response being the only remaining issue with supporting evidence in the literature.
Botulinum toxin type A is widely utilized in the cosmetic field, and it seems that all available and approved formulations are both well tolerated and effective in treating facial rhytids. The treating physician must be familiar with the differences between all the products, especially the fact that they are not interchangeable in respect to their recommended dosage.
自从肉毒毒素（BoNT）应用于面部美容领域以来，它已成为美国主要的非手术美容程序，目前有几种不同的制剂正在使用。本研究旨在综述主要制剂，以帮助医生了解产品之间的临床差异，从而提高治疗效果和患者满意度。
不同的可用制剂可根据是否存在结合蛋白分为两组。以前认为这些蛋白的存在有很大影响，但现在发现其相关性在临床上并不明显，免疫反应是文献中唯一仍有证据支持的问题。
A型肉毒毒素广泛应用于美容领域，似乎所有现有的和批准的制剂在治疗面部皱纹方面都具有良好的耐受性和有效性。治疗医生必须熟悉所有产品之间的差异，特别是它们在推荐剂量方面不能互换的事实。
